BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Intarcia Therapeutics, Inc. Executive Chairman Kurt Graves to Present at 29th Annual JP Morgan Healthcare Conference


1/4/2011 1:40:23 PM

HAYWARD, Calif., Jan. 4, 2011 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced that Kurt Graves, Executive Chairman of Intarcia Therapeutics, will present at the 29th Annual JP Morgan Healthcare Conference at 3:30 p.m. PST on Tuesday, January 11, 2011 at the Westin St. Francis Hotel in San Francisco, California.

(Logo: http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO)

About Intarcia

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the efficacy, convenience and tolerability of drug therapies. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above body temperature and to deliver them in a constant and consistent manner via the proprietary DUROS® drug delivery platform. Intarcia is pursuing a clinical stage development program for type 2 diabetes and has other programs for weight regulation to control obesity.

About ITCA 650

ITCA 650 is an investigational therapy for the treatment of type 2 diabetes using Intarcia's proprietary drug delivery technology. In 2010, Intarcia completed Phase 2 development of ITCA 650 and is planning to initiate Phase 3 development in 2011. ITCA 650 delivers exenatide therapy from a matchstick-sized, miniature osmotic pump placed subcutaneously. ITCA 650 can deliver up to a full year of therapy from a single administration in a physician's office.

About Type 2 Diabetes

According to the National Institutes of Health (NIH), "Approximately 23.6 million Americans have type 2 diabetes, which represents 7.8 percent of the U.S. population and about 1/4 of them don't even know it. In addition, we now know that at least another 57 million Americans have 'pre-diabetes.'" Diabetes is conservatively estimated to be the seventh leading cause of death in the U.S. Minority populations are disproportionately affected, particularly African Americans and Hispanics. For example, African Americans are 1.8 times more likely to develop type 2 diabetes compared to non-Hispanic whites.

According to the Centers for Disease Control and Prevention (CDC), the rate of new cases of type 2 diabetes has nearly doubled in the U.S. in the last decade with these new cases mirroring an increase in obesity rates - a leading cause of type 2 diabetes.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc. DUROS is a registered trademark of ALZA Corporation licensed to Intarcia Therapeutics, Inc. in certain fields.

SOURCE Intarcia Therapeutics, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES